Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.

Calbet M, Ramis I, Calama E, Carreño C, Paris S, Maldonado M, Orellana A, Calaf E, Pauta M, De Alba J, Bach J, Miralpeix M.

J Pharmacol Exp Ther. 2019 Aug;370(2):137-147. doi: 10.1124/jpet.119.256263. Epub 2019 May 13.

PMID:
31085698
2.

Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases.

Erra M, Taltavull J, Bernal FJ, Caturla JF, Carrascal M, Pagès L, Mir M, Espinosa S, Gràcia J, Domínguez M, Sabaté M, Paris S, Maldonado M, Hernández B, Bravo M, Calama E, Miralpeix M, Lehner MD, Calbet M.

J Med Chem. 2018 Nov 8;61(21):9551-9567. doi: 10.1021/acs.jmedchem.8b00873. Epub 2018 Oct 29.

PMID:
30351000
3.

4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships.

Roberts RS, Sevilla S, Ferrer M, Taltavull J, Hernández B, Segarra V, Gràcia J, Lehner MD, Gavaldà A, Andrés M, Cabedo J, Vilella D, Eichhorn P, Calama E, Carcasona C, Miralpeix M.

J Med Chem. 2018 Mar 22;61(6):2472-2489. doi: 10.1021/acs.jmedchem.7b01751. Epub 2018 Mar 13.

PMID:
29502405
4.

Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases.

Erra M, Taltavull J, Gréco A, Bernal FJ, Caturla JF, Gràcia J, Domínguez M, Sabaté M, Paris S, Soria S, Hernández B, Armengol C, Cabedo J, Bravo M, Calama E, Miralpeix M, Lehner MD.

ACS Med Chem Lett. 2016 Nov 30;8(1):118-123. doi: 10.1021/acsmedchemlett.6b00438. eCollection 2017 Jan 12.

5.

Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.

Calama E, Ramis I, Domènech A, Carreño C, De Alba J, Prats N, Miralpeix M.

Pulm Pharmacol Ther. 2017 Apr;43:60-67. doi: 10.1016/j.pupt.2017.01.002. Epub 2017 Jan 10.

PMID:
28087469
6.

Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.

Gràcia J, Buil MA, Castro J, Eichhorn P, Ferrer M, Gavaldà A, Hernández B, Segarra V, Lehner MD, Moreno I, Pagès L, Roberts RS, Serrat J, Sevilla S, Taltavull J, Andrés M, Cabedo J, Vilella D, Calama E, Carcasona C, Miralpeix M.

J Med Chem. 2016 Dec 8;59(23):10479-10497. Epub 2016 Nov 17.

PMID:
27933955
7.

Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.

Planagumà A, Domènech T, Pont M, Calama E, García-González V, López R, Aulí M, López M, Fonquerna S, Ramos I, de Alba J, Nueda A, Prats N, Segarra V, Miralpeix M, Lehner MD.

Pulm Pharmacol Ther. 2015 Oct;34:37-45. doi: 10.1016/j.pupt.2015.08.002. Epub 2015 Aug 10. Review.

PMID:
26271598
8.

Double-stranded RNA evokes exacerbation in a mouse model of corticosteroid refractory asthma.

De Alba J, Otal R, Calama E, Domenech A, Prats N, Gozzard N, Miralpeix M; U-BIOPRED consortium.

Clin Sci (Lond). 2015 Dec;129(11):973-87. doi: 10.1042/CS20150292. Epub 2015 Aug 5.

PMID:
26245201
9.

The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.

Gavaldà A, Ramos I, Carcasona C, Calama E, Otal R, Montero JL, Sentellas S, Aparici M, Vilella D, Alberti J, Beleta J, Miralpeix M.

Pulm Pharmacol Ther. 2014 Aug;28(2):114-21. doi: 10.1016/j.pupt.2014.05.005. Epub 2014 Jun 10.

10.

Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.

Taltavull J, Serrat J, Gràcia J, Gavaldà A, Córdoba M, Calama E, Montero JL, Andrés M, Miralpeix M, Vilella D, Hernández B, Beleta J, Ryder H, Pagès L.

Eur J Med Chem. 2011 Oct;46(10):4946-56. doi: 10.1016/j.ejmech.2011.07.054. Epub 2011 Aug 5.

PMID:
21871695
11.

Discovery of substituted phenyl urea derivatives as novel long-acting β2-adrenoreceptor agonists.

Pérez D, Crespo M, Solé L, Prat M, Carcasona C, Calama E, Otal R, Gavaldá A, Gómez-Angelats M, Miralpeix M, Puig C.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1545-8. doi: 10.1016/j.bmcl.2010.12.096. Epub 2011 Jan 6.

PMID:
21277205
12.

Effect of 5-hydroxytryptamine on neurogenic vasoconstriction in the isolated, autoperfused hindquarters of the rat.

Calama E, Ortíz de Urbina AV, Morán A, Martín ML, San Román L.

Clin Exp Pharmacol Physiol. 2005 Oct;32(10):894-900.

PMID:
16173953
13.
14.

m-CPP, a 5-HT2C receptor agonist that modifies the perfusion pressure of the hindquarter vascular bed of anesthetized rat.

Calama E, Morán A, Ortiz de Urbina AV, Martín ML, San Román L.

Pharmacology. 2005 Feb;73(2):70-5. Epub 2004 Sep 27.

PMID:
15452415
15.

Vasoconstrictor responses to 5-hydroxytryptamine in the autoperfused hindquarters of spontaneously hypertensive rats.

Calama E, Morán A, Ortiz de Urbina AV, Martín ML, San Román L.

Pharmacology. 2004 Jun;71(2):66-72.

PMID:
15118345
16.

5-Hydroxytryptamine-induced vasodilator responses in the hindquarters of the anaesthetized rat, involve beta2-adrenoceptors.

Calama E, García M, Jarque MJ, Morán A, Martín ML, San Román L.

J Pharm Pharmacol. 2003 Oct;55(10):1371-8.

PMID:
14607019
17.

Vasodilator and vasoconstrictor responses induced by 5-hydroxytryptamine in the in situ blood autoperfused hindquarters of the anaesthetized rat.

Calama E, Fernández MM, Morán A, Martín ML, San Román L.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):110-6. Epub 2002 Jun 14.

PMID:
12122496
18.

Characterization of mechanisms involved in presynaptic inhibition of sympathetic pressor effects induced by some 5-HT1 receptor antagonists.

Fernández MM, Calama E, Morán A, Martín ML, San Román L.

J Auton Pharmacol. 2000 Oct-Dec;20(5-6):313-23.

PMID:
11350497

Supplemental Content

Loading ...
Support Center